News & Updates

Show Multimedia Only

Denosumab for osteoporosis shows potential for lowering diabetes risk

02 Mar 2024 by

Treatment with denosumab in people with osteoporosis confers a protective effect against the risk of developing diabetes, according to the results of a propensity score–matched cohort study from Taiwan.

Denosumab for osteoporosis shows potential for lowering diabetes risk

02 Mar 2024

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

02 Mar 2024 by

Treatment with diazoxide choline extended-release tablet (DCCR) demonstrates good tolerability and delivers significant improvements in people with Prader-Willi syndrome, a rare, complex genetic neurobehavioral/metabolic disorder, results from an open-label study have shown.

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

02 Mar 2024

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

02 Mar 2024 by

The combination therapy of nivolumab plus cabozantinib (NIVO + CABO) continues to show long-term survival benefits and response rates over sunitinib at 55 months in patients with previously untreated advanced renal cell carcinoma (aRCC), according to updated results of the CheckMate 9ER study presented at ASCO GU 2024.

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

02 Mar 2024

Omalizumab helps reduce allergic reactions to foods in kids

01 Mar 2024 by

In young children with multiple food allergies, a treatment course with omalizumab appears to increase tolerance to peanuts and other common food allergens.

Omalizumab helps reduce allergic reactions to foods in kids

01 Mar 2024

Which factors predict mortality in advanced HCC?

01 Mar 2024

A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).

Which factors predict mortality in advanced HCC?

01 Mar 2024

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC

01 Mar 2024 by

First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC

01 Mar 2024

Low-dose epinephrine does not reduce blood loss during TURP but lowers hypotension risk

01 Mar 2024

In patients undergoing transurethral resection of prostate (TURP), treatment with low-dose epinephrine falls short of reducing blood loss during the operation but appears to minimize the incidence of hypotension, as reported in a study.

Low-dose epinephrine does not reduce blood loss during TURP but lowers hypotension risk

01 Mar 2024

Major adverse kidney events common among young people undergoing CKRT

29 Feb 2024

Almost two-thirds of youths undergoing continuous kidney replacement therapy (CKRT) have major adverse kidney events 90 days after CKRT initiation (MAKE-90), with risk factors including cardiac comorbidity, time to CKRT initiation, and liberation patterns, according to a study.

Major adverse kidney events common among young people undergoing CKRT

29 Feb 2024

Team approach to care optimizes bariatric surgery outcomes

29 Feb 2024 by

Applying the collaborative prescribing (CP) practice framework in the care of patients who have undergone bariatric surgery in Singapore is viable and helps the patients achieve the best possible outcomes, reports a research team from the Singapore General Hospital.

Team approach to care optimizes bariatric surgery outcomes

29 Feb 2024

Pembrolizumab plus lenvatinib effective against nonclear cell RCC

29 Feb 2024 by

Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.

Pembrolizumab plus lenvatinib effective against nonclear cell RCC

29 Feb 2024

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Denosumab for osteoporosis shows potential for lowering diabetes risk

Denosumab for osteoporosis shows potential for lowering diabetes risk

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

Omalizumab helps reduce allergic reactions to foods in kids

Omalizumab helps reduce allergic reactions to foods in kids

Which factors predict mortality in advanced HCC?

Which factors predict mortality in advanced HCC?

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC

Low-dose epinephrine does not reduce blood loss during TURP but lowers hypotension risk

Low-dose epinephrine does not reduce blood loss during TURP but lowers hypotension risk

Major adverse kidney events common among young people undergoing CKRT

Major adverse kidney events common among young people undergoing CKRT

Team approach to care optimizes bariatric surgery outcomes

Team approach to care optimizes bariatric surgery outcomes

Pembrolizumab plus lenvatinib effective against nonclear cell RCC

Pembrolizumab plus lenvatinib effective against nonclear cell RCC